Nomura Asset Management Co. Ltd. Sells 4,844 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Nomura Asset Management Co. Ltd. lowered its position in Blueprint Medicines Co. (NASDAQ:BPMC) by 21.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 17,713 shares of the biotechnology company’s stock after selling 4,844 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in Blueprint Medicines were worth $1,545,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also modified their holdings of the company. Quarry LP purchased a new stake in shares of Blueprint Medicines in the third quarter worth approximately $32,000. R Squared Ltd bought a new position in Blueprint Medicines in the 4th quarter valued at $51,000. Asset Management One Co. Ltd. purchased a new stake in Blueprint Medicines in the fourth quarter worth $88,000. Van ECK Associates Corp lifted its position in shares of Blueprint Medicines by 48.2% during the fourth quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock worth $97,000 after purchasing an additional 363 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new stake in shares of Blueprint Medicines during the third quarter valued at $108,000.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Wedbush reaffirmed an “outperform” rating and issued a $128.00 price target on shares of Blueprint Medicines in a research note on Friday, February 28th. Needham & Company LLC reaffirmed a “buy” rating and set a $133.00 price target on shares of Blueprint Medicines in a research note on Thursday, February 13th. Piper Sandler increased their price objective on Blueprint Medicines from $109.00 to $119.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. HC Wainwright restated a “buy” rating and set a $135.00 price objective on shares of Blueprint Medicines in a report on Friday, February 14th. Finally, JPMorgan Chase & Co. upped their target price on Blueprint Medicines from $126.00 to $129.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $124.95.

Insiders Place Their Bets

In other news, COO Christina Rossi sold 2,274 shares of the business’s stock in a transaction on Monday, March 24th. The shares were sold at an average price of $95.02, for a total transaction of $216,075.48. Following the sale, the chief operating officer now directly owns 69,266 shares of the company’s stock, valued at $6,581,655.32. The trade was a 3.18 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kate Haviland sold 1,446 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total value of $159,407.04. Following the completion of the transaction, the chief executive officer now owns 149,378 shares of the company’s stock, valued at $16,467,430.72. This trade represents a 0.96 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 31,608 shares of company stock valued at $3,319,587. Insiders own 4.21% of the company’s stock.

Blueprint Medicines Stock Performance

Shares of BPMC opened at $90.01 on Thursday. Blueprint Medicines Co. has a 12 month low of $80.68 and a 12 month high of $121.90. The stock has a fifty day moving average price of $96.75 and a 200-day moving average price of $94.02. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15. The firm has a market cap of $5.75 billion, a PE ratio of -83.34 and a beta of 0.75.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. Equities research analysts predict that Blueprint Medicines Co. will post -1.28 earnings per share for the current fiscal year.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.